Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) shares traded up 6.9% during trading on Friday . The company traded as high as $1.84 and last traded at $1.69. 10,292 shares were traded during trading, a decline of 64% from the average session volume of 28,922 shares. The stock had previously closed at $1.58.
Humacyte Price Performance
The company’s 50 day moving average is $1.84 and its two-hundred day moving average is $1.96.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Featured Articles
- Five stocks we like better than Humacyte
- How to Calculate Stock Profit
- Tesla Investors Continue to Profit From the Trump Trade
- Investing In Automotive Stocks
- MicroStrategy’s Stock Dip vs. Coinbase’s Potential Rally
- What is a Special Dividend?
- Netflix Ventures Into Live Sports, Driving Stock Momentum
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
